Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Primary Care Provider Continuity Is Associated With Improved Preventive Service Ordering During Brief Visits for Acute Symptoms
Matulis, John C. , Schilling, Jason J., North, Frederick

Mayo Clinic

Health Services Research and Managerial Epidemiology | February 7, 2019 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2333392819826262 | PMID 30793012 Get It

Background: If a patient presents for an acute care visit and sees their assigned primary care provider (PCP), they may be more likely to receive preventive and other services than a patient not seeing their assigned PCP. Methods: After exclusion of 2 visits with insufficient information, we reviewed 98 consecutive, outpatient internal medicine 15-minute acute care visits comparing patients seeing their assigned PCP with those seeing a non-PCP provider. The primary outcome, preventive service ordering, was measured in 2 ways: percentage of patient visits with any preventive service ordered and the total number of preventive services ordered as a proportion of all preventive service items due for each entire cohort. The secondary outcome of other work completed was assessed by comparing tests and consults ordered, and by counting the number of physical examination elements and discrete medical diagnoses documented. Results: The PCPs were significantly more likely than non-PCPs to order any preventive service 45% versus 17% ( P = .005; odds ratio [OR]: 4.16, 95% confidence interval [CI]: 1.45-12.0). The PCP cohort ordered a higher proportion of the total number of preventive services due compared with the non-PCP cohort (30% vs 11%; P = .002; OR: 3.4, CI: 1.5-7.7). The PCPs also addressed more medical diagnoses (2.3 vs 1.4; P = .008) and more frequently ordered tests outside the reason for that visit (40% vs 13%; P = .003; OR: 4.27, CI: 1.5-11.8). Conclusion: Patients seeing their assigned PCP in brief, acute visits have higher rates of preventive and other service ordering compared to those not seeing their assigned PCP.
Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study
Mutsaerts, Henk , Mirza, Saira Saeed , Petr, Jan , Thomas, David L. , Cash, David M. , Bocchetta, Martina , Metcalfe, Arron W.S. , Shirzadi, Zahra , Robertson, Andrew D. , Tartaglia, Maria Carmela , Mitchell, Sara, Freedman, Morris , Tang‐Wai, David F. , Keren, Ron , Laforce, Robert , Tagliavini, Fabrizio , Borroni, Barbara , Galimberti, Daniela , Rowe, James B. , Graff, Caroline , Frisoni, Giovanni B. , Finger, Elizabeth , Sorbi, Sandro , Mendonça, Alexandre de , Rohrer, Jonathan D. , MacIntosh, Bradley J. , (GENFI), GENetic Frontotemporal dementia Initiative, Andersson, Christin, Archetti, Silvana, Arighi, Andrea , Benussi, Luisa , Binetti, Giuliano, Cosseddu, Maura , Dick, Katrina M., Fallström, Marie, Fenoglio, Chiara , Fumagalli, Giorgio, Gazzina, Stefano , Ghidoni, Roberta , Grisoli, Marina , Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Mead, Simon , Meeter, Lieke , Minkelen, Rick van , Öijerstedt, Linn , Ourselin, Sébastien , Padovani, Alessandro , Panman, Jessica , Pievani, Michela, Polito, Cristina , Premi, Enrico, Prioni, Sara, Rademakers, Rosa, Redaelli, Veronica, Rossi, Giacomina , Thonberg, Håkan, Tiraboschi, Pietro , Verdelho, Ana, Warren, Jason D. , Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Binetti, Giuliano , Redaelli, Veronica , Prioni, Sara , Fumagalli, Giorgio , Frisoni, Giovanni B. , Finger, Elizabeth C. , Rowe, James B , Rohrer, Jonathan D , Padovani, Alessandro , Tartaglia, Maria Carmela , Cash, David M , Vita, Enrico De , Black, Sandra E. , Rogaeva, Ekaterina A. , Swieten, John C. van , Masellis, Mario , (GENFI), GENetic Frontotemporal dementia Initiative, Binetti, Giuliano, Fallström, Marie, Ferreira, Carlos , Fox, Nick C. , Fumagalli, Giorgio, Jelic, Vesna, Jiskoot, Lize C. , Lombardi, Gemma, Maruta, Carolina, Nacmias, Benedetta , Pievani, Michela, Premi, Enrico, Prioni, Sara, Rademakers, Rosa , Redaelli, Veronica, Rossor, Martin N. , Scarpini, Elio , Verdelho, Ana, Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Galimberti, Daniela , de Mendonça, Alexandre , Bocchetta, Martina , Tiraboschi, Pietro , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | February 2, 2019 | Volume: 142 | Issue: 4 | Pages: 1108-1120

10.1093/brain/awz039 | PMID 30847466 Get It

Abstract Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
Abstract WP161: Computational Fluid Dynamics Using SAMMPRIS CT Angiography Quantifies Pro-Atherogenic Shear Stress Linked With Post-Stenotic Flow Vortices
Honda, T , Scalzo, Fabien , Cotsonis, George, Cloft, Harry J. , Zaidat, Osama O. , Chimowitz, Marc I. , Feldmann, Edward, Kaneko, Naoki , Investigators, for the SAMMPRIS, Liebeskind, David S. , Wefers, Daniel, Fiorella, David , Derdeyn, Colin P. , Hinman, Jason D. , Investigators, for the SAMMPRIS

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.wp161 Get It

Background: Low wall shear stress (LSS) is an established cause of pro-atherogenic endothelial pathophysiology, yet it has never been demonstrated in the cerebral circulation affected by intracranial atherosclerotic disease (ICAD). Noninvasive CT angiography (CTA) computational fluid dynamics (CFD) enables high-resolution investigation of detailed post-stenotic phenomena. We used all available CTA data in the SAMMPRIS trial of ICAD to detect and quantify post-stenotic LSS. Methods: CTA source images from SAMMPRIS were reconstructed in 3D followed by geometry refinements to generate a mesh of the diseased arterial lesion and adjacent segments. CFD was performed with Ansys (ICEM, Fluent), applying reference boundary conditions with k-omega turbulence and non-Newtonian modeling of the traversing blood viscosity. 3D CFD parameter maps illustrated velocity, velocity swirling and corresponding wall shear stress. Results: 144 subjects enrolled in SAMMPRIS had CTA at baseline, including 140 with CTA source images enabling CFD. Post-stenotic velocity profiles revealed vortices in all cases, quantified by swirling and turbulent kinetic energy. These luminal flow changes were adjacent to focal regions of LSS in the post-stenotic region (Figure). Conclusions: Low wall shear stress is associated with vortices of fluid flow in CTA CFD modeling of ICAD from SAMMPRIS. CTA source images may be used to noninvasively quantify LSS and model this pro-atherogenic factor in ICAD across a wide variety of lesions. Future studies should examine the related endothelial biology and potential link with plaque evolution.
Landscape of circulating tumor DNA and tissue-based profiling in advanced cholangiocarcinoma.
Mody, Kabir , Surapaneni, Phani Keerthi, Ramanathan, Ramesh K., Ahn, Daniel H. , Starr, Jason S. , Ritter, Ashton, McMillan, Jessica , Wylie, Natasha , Roberts, Ali, Nagy, Rebecca J. , Kasi, Pashtoon Murtaza , Bekaii‐Saab, Tanios , Mahipal, Amit , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 291-291

10.1200/jco.2019.37.4_suppl.291 Get It

291 Background: Cholangiocarcinoma (CCA) has limited treatment options. Genomic analyses have led to development of targeted therapies now in clinical trials, and may enable discovery of new treatment options. However, biopsy often yields limited tissue, thus hampering tissue-based profiling opportunities. Comparative data regarding circulating tumor DNA (ctDNA) analysis and tissue based profiling in CCA are limited. Methods: We performed ctDNA NGS analysis along with tissue based profiling in pts with advanced CCA (January 2015- February 2018). ctDNA analysis was performed using Guardant 360 (Guardant Health, CA) which detects single nucleotide variants, amplifications, fusions, and specific insertion/deletion mutations in up to 73 different genes and the majority of tissue based profiling using Foundation One. The mutant allele fraction (MAF) for detected alterations was calculated relative to wild type in ctDNA. Therapeutic relevance was defined as alterations within OncoKB levels 1-3B and R1. The study was conducted in accordance with Mayo Clinic IRB requirements. Results: Among 124 pts and 139 total samples, ctDNA NGS revealed at least one genomic alteration (excluding variants of uncertain significance and synonymous mutations) in 89% of pts. Median number of alterations per pt was 3 [range, 1-15], with a median MAF of 0.42% (range, 0.1% - 94.2%). The total number of unique alterations was 321. The most commonly altered genes: TP53 (31%), KRAS (11%), FGFR2 (7%), APC and PIK3CA (each 5%) and ARID1A (3%). Amplifications were noted in 14 genes: BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, MET, MYC, PDGFRA, and PIK3CA. Tissue-based profiling was available in 57 (46%) pts, with a median of 63 days between liquid and tissue biopsy. IDH1, FGFR2, TP53 and KRAS were most common gene mutations found in pts who had both liquid and tissue biopsy done. (Comparative results to be shown). Conclusions: ctDNA plasma profiling of pts with advanced CCA is a feasible alternative method to gather comprehensive genomic data. Further larger cohort studies comparing landscape of alterations seen on ctDNA versus tissue-based assays are needed.
Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC).
Mody, Kabir , Surapaneni, Phani Keerthi, Ahn, Daniel H. , Starr, Jason S. , Ritter, Ashton, McMillan, Jessica , Wylie, Natasha , Roberts, Ali, Nagy, Rebecca J. , Kasi, Pashtoon Murtaza , Borad, Mitesh J. , Mahipal, Amit , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 289-289

10.1200/jco.2019.37.4_suppl.289 Get It

289 Background: PDAC has limited treatment options. Genomic analyses have led to development of targeted therapies now in several clinical trials, and may enable the discovery of new treatment options. However, biopsy often yields limited tissue, thus hampering tissue-based profiling opportunities. Data regarding circulating tumor DNA (ctDNA) profiling in PDAC during real time clinical practice is limited. Methods: We performed ctDNA NGS analysis in pts with advanced PDAC (December 2014–August 2018). ctDNA analysis was performed using Guardant 360 (Guardant Health, CA), which detects single nucleotide variants, amplifications, fusions, and specific insertion/deletion mutations in up to 73 different genes. The mutant allele fraction (MAF) for detected alterations was calculated relative to wild type in ctDNA. Therapeutic relevance (TR) was defined as possible treatments within OncoKB levels 1-3B and R1. The study was conducted in accordance with Mayo Clinic Institutional Review Board requirements. Results: Among 171 pts and 206 total samples, ctDNA NGS revealed at least one genomic alteration in 150 pts (88%). Median number of alterations per patient was 3 [range, 1-15]. The total number of unique alterations was 450 with the most commonly altered genes being: TP53 (181 alterations, 40%), followed by KRAS (118 alterations, 26%), CDKN2A (23 alterations, 5%), SMAD4 (15 alterations, 3%), EGFR (11 alterations, 2.4%), PIK3CA (9 alterations, 2%), GNAS (8 alterations, 1.5%). Amplifications were noted in 16 genes, including BRAF, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA and RAF1. Therapeutically relevant alterations were seen in 95 pts of the 150 pts (63%). Tissue based profiling (Results to be shown) was done in 56 (33%) pts of total 171 pts with a median of 130 days between ctDNA and tissue biopsy. KRAS and TP53 were the most common gene mutations found in patients with both liquid and tissue biopsy results. Conclusions: ctDNA plasma profiling of pts with advanced PDAC is a feasible alternative method to gather comprehensive genomic data.
Impact of obesity upon the survival of cholangiocarcinoma patients.
Surapaneni, Phani Keerthi, Li, Zhuo , Vemireddy, Lalitha Padmanabha, Starr, Jason S. , Ritter, Ashton, McMillan, Jessica , Wylie, Natasha , Mody, Kabir , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 288-288

10.1200/jco.2019.37.4_suppl.288 Get It

288 Background: Obesity is a risk factor for developing cholangiocarcinoma (CCA). However, the effect of obesity on survival of CCA is unclear. The primary aim of this study was to analyze the impact of obesity upon overall survival of CCA patients. Secondary aims were to analyze impact of obesity upon other disease characteristics such as tumor site, stage, age, sex, BMI and Ca 19-9. Methods: A total of 411 unique pts diagnosed with CCA at Mayo Clinic Florida between 2000 and 2018 were retrieved from our collective SDMS database. Variables evaluated included:demographics, Body Mass Index (BMI), AJCC stage, tumor location and Ca 19-9.A total of 185 pts had all data available pertaining to these variables. We further restricted the analysis to pts with intrahepatic CCA classified BMI as per CDC criteria normal (18.5-25kg/m2), overweight (25-29.9kg/m2) and obese (≥30 kg/m2), thus leaving a total of 152 pts. Continuous and categorical variables were compared across BMI groups using Chi-squared or Fisher’s exact test. Overall survival rates after diagnosis at 1, 2 and 3 years were estimated using Kaplan-Meier method. Results: Among 152 pts included in the study, 28% were normal weight, 40% were overweight and 32% were obese. The overall survival rate at 1, 2 and 3 years for normal weight pts with all stages combined was 54.1%, 35%, and 30.7%, respectively. The overall survival rate at 1, 2 and 3 years for overweight pts with all stages combined was 59.7 %, 32.6%, and 25.4%, respectively. The overall survival rate at 1, 2 and 3 years for obese pts with all stages combined was 63.9%, 37.6%, and 26.7%, respectively(p = 0.8766). Multivariate analysis demonstrated is no significant difference in overall survival for obese pts compared to normal or overweight pts.(Table to be shown) However it showed, gender and Ca19-9 were statistically significant predictors of overall survival, with males and pts with Ca19-9≥100 doing worse (HR1.65 (CI = 1.05, 2.61, p = 0.031) and HR 2.31 (CI = 1.49, 3.59, p = < 0.01), respectively). Conclusions: BMI did not make a significant impact on the overall survival, though there may be a trend toward worse OS for ptswith higher BMI. A larger, stage focused evaluation is warranted for further exploration of this trend.
Proceedings from the Ice Hockey Summit III: Action on Concussion
Smith, Aynsley M., Alford, Patrick A., Aubry, Mark, Benson, Brian W., Black, Amanda M. , Brooks, Alison, Burke, Charles J., Eaves, Michael, Eickhoff, Chad, Erredge, Kristen, Farrell, Kyle , Finnoff, Jonathon, Giza, Christopher C. , Greenwald, Richard M., Hoshizaki, Blaine, Huston, John , Jorgensen, Janelle, Leaf, Matthew, Leddy, John J. , Margarucci, Kevin, Munce, Thayne A. , Prideaux, Cara C. , Roberts, William O. , Shen, Francis X. , Soma, David , Tabrum, Mark, Stuart, Michael, Wethe, Jennifer V. , Whitehead, James R., Wiese‐Bjornstal, Diane M. , Dodick, David, Joyner, Michael, Krause, David, Prideaux, Cara, Stuart, Michael B, Wethe, Jennifer, Farrell, Kyle J , Alford, Patrick W. , D’Arcy, Ryan C.N. , Dodick, David W. , Fraser, Douglas D. , Joyner, Michael J. , Krause, David A. , LaVoi, Nicole M. , Margulies, Susan Sheps , Mihalik, Jason P. , Oeur, Anna , Stuart, Michael J. , Wethe, Jennifer V

Mayo Clinic

Current Sports Medicine Reports | January 29, 2019 | Volume: 18 | Issue: 1 | Pages: 23-34

10.1249/jsr.0000000000000557 | PMID 30624332 Get It

The Ice Hockey Summit III provided updated scientific evidence on concussions in hockey to inform these five objectives: 1) describe sport-related concussion (SRC) epidemiology, 2) classify prevention strategies, 3) define objective, diagnostic tests, 4) identify treatment, and 5) integrate science and clinical care into prioritized action plans and policy. Our action plan evolved from 40 scientific presentations. The 155 attendees (physicians, athletic trainers, physical therapists, nurses, neuropsychologists, scientists, engineers, coaches, and officials) voted to prioritize these action items in the final Summit session. 1) Establish a national and international hockey data base for SRC at all levels, 2) eliminate body checking in Bantam youth hockey games, 3) expand a behavior modification program (Fair Play) to all youth hockey levels, 4) enforce game ejection penalties for fighting in Junior A and professional hockey leagues, 5) establish objective tests to diagnose concussion at point of care (POC), and 6) mandate baseline testing to improve concussion diagnosis for all age groups. Expedient implementation of the Summit III prioritized action items is necessary to reduce the risk, severity, and consequences of concussion in the sport of ice hockey.
Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review
Kvetan, Vladimír, Farmer, Joseph C. , Sessler, Curtis N., Christman, John W. , D’Agostino, Rhonda, Gregg, Sara, Khan, Roozehra, Kapu, April N. , Masur, Henry , Mehta, Gargi, Moore, Jason E. , Oropello, John M., Price, Kristen , Hite, R. Duncan , Farmer, J Christopher, Diaz-Gomez, Jose, Pastores, Stephen M. , Coopersmith, Craig M , Díaz‐Gómez, José L.

Mayo Clinic

Critical Care Medicine | January 26, 2019 | Volume: 47 | Issue: 4 | Pages: 550-557

10.1097/ccm.0000000000003637 | PMID 30688716 Get It

Objectives: To assess—by literature review and expert consensus—workforce, workload, and burnout considerations among intensivists and advanced practice providers. Design: Data were synthesized from monthly expert consensus and literature review. Setting: Workforce and Workload section workgroup of the Academic Leaders in Critical Care Medicine Task Force. Measurements and Main Results: Multidisciplinary care teams led by intensivists are an essential component of critical care delivery. Advanced practice providers (nurse practitioners and physician assistants) are progressively being integrated into ICU practice models. The ever-increasing number of patients with complex, life-threatening diseases, concentration of ICU beds in few centralized hospitals, expansion of specialty ICU services, and desire for 24/7 availability have contributed to growing intensivist staffing concerns. Such staffing challenges may negatively impact practitioner wellness, team perception of care quality, time available for teaching, and length of stay when the patient to intensivist ratio is greater than or equal to 15. Enhanced team communication and reduction of practice variation are important factors for improved patient outcomes. A diverse workforce adds value and enrichment to the overall work environment. Formal succession planning for ICU leaders is crucial to the success of critical care organizations. Implementation of a continuous 24/7 ICU coverage care model in high-acuity, high-volume centers should be based on patient-centered outcomes. High levels of burnout syndrome are common among intensivists. Prospective analyses of interventions to decrease burnout within the ICU setting are limited. However, organizational interventions are felt to be more effective than those directed at individuals. Conclusions: Critical care workforce and staffing models are myriad and based on several factors including local culture and resources, ICU organization, and strategies to reduce burden on the ICU provider workforce. Prospective studies to assess and avoid the burnout syndrome among intensivists and advanced practice providers are needed.
Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
Beckmann, Pauline J. , Larsson, Alex T. , Ostergaard, Jason, Wagner, Sandra, Rahrmann, Eric P. , Shamsan, Ghaidan A. , Otto, George M. , Williams, Rory L. , Wang, Jun , Lee, Catherine , Tschida, Barbara R. , Das, Paramita , Dubuc, Adrian M. , Moriarity, Branden S. , Picard, Daniel , Wu, Xiaochong , Rosemarie, Quincy , Krebs, Ryan D., Molan, Amy M. , Demer, Addison M. , Frees, Michelle M. , Rizzardi, Anthony E., Schmechel, Stephen C. , Jenkins, Robert B. , Wechsler‐Reya, Robert J. , Odde, David J. , Taylor, Michael D. , Sarver, Aaron L. , Largaespada, David A. , Rahrmann, Eric P , Shamsan, Ghaidan A , Williams, Rory L , Picard, Daniel , Rosemarie, Quincy , Odde, David J , Larson, Jon D. , Wagner, Sandra, Tschida, Barbara R , Rodríguez, Fausto J. , Krebs, Ryan D., Eberhart, Charles G. , Huang, Annie , Largaespada, David A.

Mayo Clinic

Cancer Research | January 23, 2019 | Volume: 79 | Issue: 5 | Pages: 905-917

10.1158/0008-5472.can-18-1261 | PMID 30674530 Get It

Abstract Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble human Sonic hedgehog and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 activation. This represents the first genetically induced mouse model of CNS-PNET and a rare model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET. Significance: A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET.